reason report
bottom line alexion almost exclus valu basi
complement inhibitor soliris/ultomiri franchis although last
month compani invest rare diseas program
via acquisit licens agreement far investor mainli
ignor program note begin explor valu
non-compl program oral small molecul
chelat facilit remov copper bodi liver
product develop lifelong treatment patient
wilson diseas genet disord copper metabol associ
neurolog metabol manifest copper accumul
alexion secur right product acquisit
wilson phase data suggest
differenti exist therapi faster onset deeper
durabl efficaci greater breadth benefit neurolog
hepat diseas respons analysi suggest diseas
signific opportun alexion leverag alexion core capabl
develop commerci novel medicin rare diseas
signific residu medic need market model wilson diseas
suggest could achiev pos-adjust peak sale
analysi wd market suggest uptak
could greatest patient neurolog symptom assum
phase studi demonstr lower rate acut neurolog
worsen improv neurolog symptom safeti benefit
could drive uptak chelat intoler patient uptak patient
stabl chelat therapi includ major patient liver
manifest could acceler result anticip
phase liver biopsi studi liver de-copp confirm
correl reduct serum free copper measur base
analysi current valu potenti
valu clinic develop expand indic
success signific upsid could come find higher diagnosi
preval rate current model effect diseas
identif implement
estim current market wd therapi
us ww base report sale
exist medicin estim share sale wd
number patient treatment pattern us ex us
market estim market increas
us ww assum come market
chang treatment adopt persist absolut basi
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
forecast launch gener revenu
grow incorpor
revenu compani model alexion probabl
success po result revenu contribut
revenu contribut increas total
revenu forecast alexion leav
adjust revenu forecast consensu
basi research inclus revenu compani
model price target increas
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi upcom label expans on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain futur
find alexion well posit grow ep doubl digit next five year
alexion almost exclus valu basi complement inhibitor soliris/ultomiri
franchis although last month compani invest rare diseas
program via acquisit licens agreement far investor mainli ignor
program note begin explor valu non-compl program
oral small molecul chelat facilit remov copper bodi
liver product develop lifelong treatment patient wilson
diseas genet disord copper metabol associ neurolog metabol
manifest copper accumul alexion secur right product
acquisit wilson therapeut phase data suggest
differenti exist therapi faster onset deeper durabl efficaci
greater breadth benefit neurolog hepat diseas respons analysi suggest
diseas signific opportun alexion leverag alexion core capabl
develop commerci novel medicin rare diseas signific residu medic
need market model wilson diseas suggest could achiev pos-adjust
peak sale analysi wd market suggest uptak could
greatest patient neurolog symptom assum phase studi demonstr lower
rate acut neurolog worsen improv neurolog symptom safeti
benefit could drive uptak chelat intoler patient uptak patient stabl chelat
therapi includ major patient liver manifest could acceler
result anticip phase liver biopsi studi liver de-copp confirm
correl reduct serum free copper measur base analysi
current valu potenti valu clinic develop
expand indic success signific upsid could come find higher diagnosi
preval rate current model effect diseas identif
estim current market wd therapi us ww
base report sale exist medicin estim share sale wd
number patient treatment pattern us ex us market estim
market increas us ww assum
come market chang treatment adopt persist absolut basi
forecast launch gener revenu
grow incorpor revenu compani model
alexion probabl success po result revenu contribut
revenu contribut increas total revenu
forecast alexion leav adjust revenu forecast
consensu basi research inclus revenu
compani model price target increas
exhibit current estim wd market
metabol disord primarili affect liver brain
estim potenti address us patient popul underli wd wilson
diseas base review medic literatur due heterogen present
symptom wd significantli underdiagnos current diagnosi rate estim
rang estim current
patient diagnos treat us alon use similar preval diagnosi
rate estim address eu popul patient patient
wd driven defect product protein liver essenti
regul bodi copper level excess copper toxic mani cell tissu throughout
bodi primari diseas manifest reflect sensit liver brain
copper-medi damag untreat wd fatal treatment involv control
remov bodi burden excess copper delay diagnosi treatment lead
signific neuropsychiatr disabl well progress liver diseas includ cirrhosi
exhibit system impact elev circul copper level
age symptomat onset subsequ clinic diagnosi wd vari wide
year age publish report indic averag age diagnosi year given
younger age present estim address patient popul
patient us eu base elig updat phase
protocol allow enrol patient year age
exhibit averag patient time wd diagnosi
wd patient year age
major patient diagnos wd present hepat symptom follow
neurolog symptom approxim patient present overlap hepat
neurolog manifest patient asymptomat time diagnosi liver
neurolog diseas progress gener correl durat magnitud
excess copper exposur liver injuri usual preced neurolog injuri howev
appear neurolog symptom prior hepat symptom uncommon
frequent occur patient diagnos older age treat physician commonli
hepatologist greater heterogen specialist prescript penicillamin given
indic beyond wd alon ra cystinuria
exhibit present symptom diagnosi wd
exhibit specialist share rx common wd treatment
diagnosi rate suggest signific opportun market expans
wd monogen disord transmit autosom recess manner gene
locat chromosom mani differ patholog gene variant
identifi unlik genet disord cystic fibrosi spinal muscular atrophi
sma genotyp directli impact treatment decis wd genotyp signific
driver treatment plan prognosi genet test use primarili diagnost purpos
due low correl genotyp phenotyp treatment decis larg guid
clinic factor symptomatolog copper level safeti toler exist
therapi conveni physician preference/experi although genet test
rel easi obtain usual reserv confirm diagnosi patient symptom
famili histori wd genet screen test usual reserv asymptomat patient
confirm famili histori wd account patient wd due
vagu heterogen natur present symptom wd often describ
great imit requir high clinic index suspicion accur time diagnosi
therefor without high degre clinic suspicion diagnosi often delay miss
diagnosi wd establish use score system patient assign point
leipzig score base presenc variou clinic find symptom test result
leipzig score establish diagnosi wd genet test alon provid suffici
basi diagnosi mutat detect chromosom
estim address patient highli depend diagnosi rate model
assum current diagnosi rate upward trend coincid launch
expect alexion promot effort lead higher rate genet test
screen confirmatori set
exhibit leipzig score system wd
kayster-fleisch ringsliv copper absenc uln posit symptomsurinari copper absenc acut uln ceruloplasminmut analysisnorm one mutat neg hemolyt establish possibl test need unlikelyclin findings/symptomstest resultstot leipzigscor alexion inc
exhibit svb leerink estim wd diagnosi rate address popul
base discuss medacorp kol review medic literatur believ
current treatment recommend primarili guid physician experi opinion
lead author lesser extent clinic data wd studi observ
retrospect non-control natur despit variat opinion optim treatment
regimen amongst kol within medic literatur observ broad consensu
regard need prompt initi therapi consist mainten
patient entir lifetim diagnosi wd made treatment nave patient
hepat neurolog symptom gener requir potent frequent dose copper
chelat induc rapid copper lower promot stabil improv symptom
initi therapeut agent usual continu year patient gener follow
manag physician everi month copper level and/or symptom
stabil patient switch less aggress mainten regimen gener
consist less frequent dose therapeut agent assum well toler
current clear guidelin switch agent presenc symptomat
progress patient gener continu agent indefinit least
intermitt patient enter mainten therapi follow-up decreas
everi month month discuss kol suggest patient gener remain
therapi lifetim unless safeti toler issu necessit switch
anoth pharmacolog agent discontinu therapi recommend due risk
diseas progress well higher risk sever advers event includ acut
multipl drug approv treat wilson diseas past decad
common diseas modifi treatment categori copper chelat bind copper
blood facilit remov urinari excret chelat approv treat
wilson diseas includ penicillamin cuprimin trientin syprin trientin
dihydrochlorid gener categori effect drug zinc galzin
us wilzin europ act induc product metallothionein block
absorpt copper intestin tract action deplet accumul copper
prevent reaccumul zinc effect shown year
consider experi oversea major advantag zinc therapi rel mild safeti
profil howev consider less potent penicillamin trientin therefor
requir frequent administr inconveni meal-bas dose gener reserv
asymptomat patient without signific liver impair
patient receiv earli diagnosi prompt initi therapi usual excel
prognosi life expect approach gener popul observ studi
suggest patient diagnos younger age longer life expect compar
patient diagnos later life sever liver dysfunct delay diagnosi lack
adequ treatment detriment consequ particularli patient neurolog
symptom symptom irrevers case patient earli hepat
involv usual respond well therapi publish report suggest
improv rate hepat function
model assum patient remain entir lifetim given potenti
potent chelat effect expect patient initi therapi daili
dose regimen first year subsequ switch less frequent mainten
regimen copper level symptom stabil
alexion commerci strategi well posit wd market given low degre price
competit brand gener therapi consist exist view rare
diseas market believ low risk price pressur effect novel wd
therapi incumb manufactur abl command rel high price hundr
thousand per year particularli consid cumul cost therapi
patient entir lifetim bausch health formerli valeant manufactur cuprimin syprin
lead brand therapi wd bausch report us revenu
cuprimin syprin respect report revenu
respect accord pricerx estim wac penicillamin
current rang per tablet cuprimin bausch per dose gener
penicillamin repres discount brand op previous manufactur
depen titratab anoth brand version penicillamin wac howev suppli
disrupt compani manufactur facil puerto rico follow hurrican maria
limit avail product unclear timelin return
market recent approv copper chelat trientin also demonstr abil
sustain high price wac rang per tablet brand syprin bausch
per tablet gener trientin hcl zinc acet command lowest price wac
galzin per tablet price consist like total
annual treatment cost penicillamin trientin zinc acet
review iqvia data bausch health financi file suggest realiz price
like wac price impli net price cuprimin syprin
base iqvia script data estim total annual treatment cost
penicillamin trientin zinc acet believ posit differenti
novel therapi would abl command premium par slightli higher
cuprimin although size premium dictat efficaci safeti result
phase trial base-cas assum premium cuprimin wac
net realiz price account addit discount even allow
discount total annual treatment cost per patient view like initi
increas
exhibit wac per dose current approv wd therapi
drugbrandmanufacturernumb tabletsprice/doseawac/dosecupriminebausch current avail due supply/manufactur disruptionspenicillaminetrientinezinc acet alexion inc
exhibit wac per dose current approv wd therapi
exhibit estim iqvia actual wd sale
pauciti outcom data consist vari treatment pattern
due lack invest exist manufactur pauciti
rigor clinic data evalu outcom commonli prescrib agent base
review primari literatur find major publish report observ
retrospect natur lack precis defin neurolog hepat outcom
weak treatment evid consist heterogen treatment pattern across wd
believ rigor studi agent potenti easili establish new
standard care diseas assum efficaci safeti versu exist therapi
demonstr random phase focu trial base iqvia data estim
treat wd patient chelat penicillamin trientin remain
patient zinc therapi kol discuss consist iqvia data indic
trientin commonli use agent despit approv second-lin due lower
rate practic trientin rel market share like higher iqvia data suggest
sinc penicillamin approv indic diseas rheumatoid arthriti
despit kol recommend switch therapi real-world set seem
patient switch therapi basi safeti toler treatment burden
common reason discontinu therapi medic side effect
howev non-clin factor cost non-compli result patient
exhibit estim us market share current wd therapi
chelat lack desir efficaci neurolog patient
approxim patient initi therapi wd neuropsychiatr symptom
higher level baselin impair correl wors neurolog outcom exist
therapi approxim patient pre-exist neurolog symptom declin
initi therapi respons favor trientin penicillamin rate neurolog
improv stabil gener lower hepat symptom acut neurolog
worsen frequent complic treatment occur patient initi
chelat therapi first time higher rate earli neurolog worsen
observ patient baselin neurolog symptom prior initi therapi
compar patient without neurolog symptom although precis mechan earli
neurolog worsen known believ consequ transient elev
serum free copper deposit brain tissu due initi mobil releas
liver sinc promot biliari copper excret oppos extract serum
lower rate acut neurolog worsen expect expect support
phase data show essenti episod acut neurolog worsen apart
patient pre-exist activ neurolog symptom
ideal agent lack due vari benefit drawback
among exist medicin penicillamin effect signific limit due poor
safeti toler signific treatment burden penicillamin introduc
approv first-lin agent wd approv indic includ cystinuria well
sever activ rheumatoid arthriti patient fail convent therapi seriou
lead treatment discontinu occur patient includ earli
late-stag reaction hypersensit reaction arthralgia leukopenia proteinuria
acut neurolog worsen patient inconveni major limit penicillamin due
refriger storag requir well frequent dose four-tim per day
patient must take penicillamin either hour meal hour minim lower
absorpt rate occur presenc food
trientin anoth chelat approv second-lin agent accord
kol trientin often prefer first-lin agent primarili due lower rate
includ sideroblast anemia acut neurolog worsen trientin similar issu
inconveni requir frequent meal-bas dose
zinc acet third agent avail wd oppos penicillamin trientin
increas urinari copper excret zinc work primarili gi tract limit copper absorpt
zinc far less potent copper chelat therefor usual reserv use
mainten set patient less sever diseas approxim patient take
zinc therapi zinc report safe patient neurolog symptom low
rate neurolog worsen common includ gi-rel issu gastriti
pancreat diarrhea multipl formul oral zinc exist includ zinc acet zinc
glucon zinc sulfat zinc acet potent form avail prefer due
lower toler issu zinc sulfat patient requir take zinc therapi three four
time per day meal administr necessari optim efficaci
exhibit benefit drawback current wd therapi
inconveni non-compliance signific barrier effect treatment
non-compliance rate current treatment report rang
clear differ across medic recent paper patient queri
inconveni aspect wd therapi three commonli report factor includ
meal-bas dose cost dose inconveni believ
potenti becom therapi choic among patient physician due lack
meal-bas dose requir lower frequenc administr faster onset effect
potenti lower rate neurolog worsen chelat associ addit
inconveni includ refriger requir need iron zinc
supplement administ differ time chelat due off-target bind
result iron zinc defici
exhibit survey report dose frequenc current wd therapi
cuprimin penicillamin syprin trientin galzin zinc acet approv year wd linehepat improv improv neurolog due advers dose stomach dose requirementyesyesyespotenti need and/or zinc supplementationyesyesyespoor storage/requir refrigerationyesyesnogreen benefit red drawbackbackgroundefficacyinconveniencesafety/toler alexion inc
phase data show potent de-copp abil improv safeti profil
formerli de-copp agent copper bind affin
versu exist chelat uniqu bind copper liver promot biliari excret unlik
exist chelat bind copper serum promot renal clearanc
phase proof-of-concept studi single-arm open-label trial patient wd
leipzig score initi trial protocol allow twice daili dose maximum
daili dose daili due develop high alt patient receiv
protocol amend limit maximum daili dose
enrol subject complet studi period studi patient mostli
treatment-n new treatment prior therapi less
day prior enrol neurolog symptom present major patient
patient least one neurolog abnorm baselin commonli compris
gait ataxia primari outcom reduct serum non-
ceruloplasmin ncc biomark circul free copper level secondari endpoint
includ safeti toler time normal ncc level chang neurolog
liver diseas measur symptom qualiti life data
open label extens studi report part confirm
reduct ncc level rapid sustain correl improv
disease-rel disabl neurolog statu baselin mean ncc level mol/l
decreas upper limit normal mol/l week week mean
reduct ncc level deeper reduct mean ncc level mol/l
repres statist signific declin baselin seventy-on percent
patient achiev ncc reduct upper limit normal ncc reduct
correl improv disabl uwdr part ii score neurolog statu uwdr
part score mean improv reach statist signific around week
sustain week liver function assess measur inr ast
albumin meld score show stabil thru week
initi week studi period report patient
patient develop total seriou psychiatr natur
occur patient gi-rel event report patient treatment
discontinu occur patient discontinu due elev liver enzym
discontinu due psychiatr symptom prevent adher studi protocol one
discontinu due potenti neurolog worsen patient psychiatr
discontinu either stabl improv uwdr part score studi period
therefor discontinu attribut case acut neurolog
deterior observ within first week although one case neurolog
deterior occur patient week patient exhibit activ neurolog
deterior prior enrol discontinu deem relat diseas
progress howev causal studi drug rule
exhibit stabil liver function week
exhibit neurolog improv thru week
phase trial establish superior broadli
phase enrol start random open-label trial evalu daili dose alxn-
versu standard care therapi patient year age leipzig score
exclus criteria includ presenc sever advanc liver diseas sever neurolog
diseas patient esrd similar phase studi primari outcom
measur percentag chang free copper level measur non-
ceruloplasmin-copp ncc level week compar baselin alexion indic
confid select primari outcom measur suggest
agreement fda ema ncc reduct approv endpoint
secondari measur includ assess chang hepat statu disabl statu
neurolog statu clinic symptom approxim patient expect
initi enrol enabl evalu patient approxim patient
expect treatment nave defin therapi receiv within last day
investig free choos soc therapi a-priori requir distribut
trientin penicillamin zinc compar arm manag expect enrol
complet blind interim analysi expect provid option
increas enrol top-lin efficacy/safeti data expect pend posit
result could enabl approv launch phase subject elig enrol
extens studi month addit liver biopsi studi plan
assess confirm direct liver de-copp effect expect biopsi
studi necessarili part file packag howev posit result could acceler uptak
patient asymptomat exhibit hepat manifest
competit threat near term
believ opportun new treatment wd larg ignor result
low risk competit entri novel therapi review competit landscap
suggest potenti competitor primarili earli stage develop base
riskier treatment modal gene therapi potenti competitor identifi
includ gene therapi candid well oral small molecul
liver-direct aav treat underli caus wd increas
product truncated-but-funct protein liver pre-clin data demonstr
product transgen protein improv copper balanc mice earli
later-stag diseas grant orphan drug design fda eu
march acquir stake vivet anoth
gene therapi candid pre-clin develop ultragenyx op preclin data
demonstr signific reduct liver copper level treat versu untreat anim
accord ultragenyx disclosur ind file anticip occur gene
therapi hold promis mimick benefit liver transplant produc function
protein estim year time horizon potenti gene therapi launch base
zolgensma initi ind approv septemb subsequ approv may
indic market entri would like occur approxim account
potenti disrupt effect success gene therapi treatment wd
model probability-weight scenario gene therapi enter market result
earlier rapid eros market share prior expect us loss
exclus loe due inher risk associ liver-direct gene therapi
includ dose-rel liver toxic well potenti wane durabl assign
probability-weight scenario occur base-cas scenario probability-
weight includ gene therapi entri eros market share occur
loe us eu oral small molecul describ
highli select copper chelat pre-clin data demonstr inhibit copper-
induc cell death ex-vivo model wd well reduct brain liver copper
mous model wd pre-clin develop privat held depym
affili spring harbor laboratori futur develop plan yet
disclos believ second small-molecul entrant would like face steeper hurdl
approv uptak abl becom standard-of-car wd therefor
assum entri addit small molecul agent prior loe model
base discuss alexion manag expect benefit
patent protect beyond period orphan drug exclus would year us
year eu base orphan design therefor assum us gener entri
eu gener entri
expect initi uptak neurolog patient treatment failur
base-cas scenario assum us approv eu approv base
expect abl demonstr superior ncc lower versu exist
therapi addit assum abl show superior safeti profil demonstr
lower rate acut neurolog worsen treatment-rel discontinu therebi
support rapid uptak patient neurolog symptom well patient
intoler deem fail chelat therapi delay uptak patient
stabl chelat regimen year pend confirm enhanc liver decopp effect
subsequ liver biopsi studi believ like demonstr improv liver
histolog given uniqu mechan action direct liver activ given small size
address wd popul rel concentr prescrib base assum
alexion success promot facilit uptak also drive higher
genet test rate expand number address patient
believ abl command premium cuprimin base
expect superior efficaci safeti expect averag treatment durat increas
along higher adopt rate time
assign po develop success base analysi review wd
phase data given manag disclosur expect benefit
patent protect beyond period exclus orphan drug design year
us year eu exclus period account gener entri us
eu
ad model increas pt
ad forecast current alexion model increas revenu estim
revenu growth rate higher period
revenu consensu ep increas
annual ep growth rate period ep higher
consensu base chang pt increas
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
ratio discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use termin
growth rate post give current valu averag three valuat
methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
european hear com patent
combin waiha pv ph data
later
combin waiha pv ph data
later
biomark endpoint prelud larger pivot
sound like patient clinic poc studi
initi phase
bridg trial pnh indic
phase studi investig
add-on current standard-of-car therapi
svb leerink llc research compani file
analysi stock price svb leerink target alexion
multipl ep svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biotech co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
